Business · India Bureau
Divi's Laboratories Market Cap Surges Past Rs 3 Lakh Crore
The pharmaceutical company has joined India's elite market capitalisation club, driven by robust revenue expansion and margin improvements. Strong investor sentiment around its custom synthesis business has fuelled the rally.
LSN India ·
Divi's Laboratories has crossed the Rs 3 lakh crore market capitalisation milestone, reflecting renewed investor confidence in the pharmaceutical manufacturer. The stock rally underscores market optimism around the company's growth trajectory and operational performance.
The Hyderabad-based firm's ascent into the three-lakh-crore club has been underpinned by a 35% revenue growth trajectory, signalling accelerating business momentum across its portfolio. Alongside top-line expansion, the company has demonstrated operational leverage, with margin expansion reinforcing the improvement in profitability metrics.
Investor enthusiasm has been particularly buoyed by positive sentiment around Divi's custom synthesis vertical, which specialises in manufacturing active pharmaceutical ingredients and pharmaceutical intermediates for global clients. This business segment has emerged as a key growth driver, capitalising on rising global demand for outsourced drug manufacturing and India's competitive positioning in the sector.
The market capitalisation milestone positions Divi's Laboratories among India's most valued pharmaceutical enterprises, reflecting the sector's continued appeal to investors amid favourable industry tailwinds. The company's performance adds to broader optimism around India's pharmaceutical industry, which has established itself as a significant global player in generic drugs and contract manufacturing services.